Latest Breaking News On - Lower gastrointestinal - Page 1 : comparemela.com

Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum

Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiYonghong liAfsaneh barziDan edelsteinHealth forumEliza hall institute of medical researchEliza hall instituteJohns hopkins school of medicinePeter maccallum cancer centreQuest diagnosticsAmerican society of clinical oncologyDuarte cancer centerHaystack oncologyMedical researchJeanne tie

Blood-Based MRD Test For Cancer Recurrence Can Generate Cost Savings In Colorectal Cancer Treatment, Finds Study In JAMA Health Forum

Blood-Based MRD Test For Cancer Recurrence Can Generate Cost Savings In Colorectal Cancer Treatment, Finds Study In JAMA Health Forum
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiAfsaneh barziDan edelsteinYonghong liEliza hall instituteHealth forumQuest diagnosticsAmerican society of clinical oncologyPeter maccallum cancer centreDuarte cancer centerJohns hopkins school of medicineEliza hall institute of medical researchHaystack oncologyMedical researchJeanne tie

NCCN 2024 Annual Conference Shares Cancer Care Updates for Practical, Immediate Use in Practice

NCCN 2024 Annual Conference Shares Cancer Care Updates for Practical, Immediate Use in Practice
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Wenora johnsonRandam perkinsErinr foxLaura brayMoffitt cancer centerUniversity of utah health careNational comprehensive cancer networkNational comprehensive cancerChief executive officerChief change makerUtah healthCancer survivorPatient advocatePractice guidelinesNegative breastLower gastrointestinal

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United statesBin chenJohn cunninghamChinwe ukomaduCrohn diseasevedolizumabCancer centerInternational blood marrow transplant researchHematopoietic cell transplant therapy programExchange commissionEuropean unionEuropean medicines agencyTakeda pharmaceutical company limitedYi bin chenHematopoietic cell transplantCell therapy programMass general cancer

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

United statesBin chenJohn cunninghamJun saitoCancer centerInternational blood marrow transplant researchHematopoietic cell transplant therapy programExchange commissionEuropean unionEuropean medicines agencyTakeda pharmaceutical company limitedMet its primary efficacy endpointClinically meaningful intestinalFree survivalNew safety signals were seenVedolizumab compared